A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL
NCT04194190 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-09-04
Summary
A single patient will be treated with Individual Patient TCR-Transduced PBL
Interventions
- DRUG
-
Individual Patient TCR-Transduced PBL
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
lead NIH
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
NCT02556463 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
NCT03970382 ·Status: SUSPENDED ·Phase: PHASE1
-
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
NCT02111850 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
NCT00910650 ·Status: COMPLETED ·Phase: PHASE2
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT04119024 ·Status: RECRUITING ·Phase: PHASE1
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
NCT02133196 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
NCT03918252 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
NCT02153905 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
NCT04536922 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
NCT02644369 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
NCT02414269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor
NCT03615313 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
NCT02350673 ·Status: COMPLETED ·Phase: PHASE1
-
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
NCT04013334 ·Status: UNKNOWN ·Phase: PHASE2
-
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
NCT02706392 ·Status: TERMINATED ·Phase: PHASE1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00045357 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
NCT02621021 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
NCT03490669 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
NCT06485219 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
NCT00509496 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
NCT00096941 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928 ·Status: TERMINATED ·Phase: PHASE2
-
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
NCT00002505 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
NCT05276310 ·Status: RECRUITING ·Phase: PHASE1
-
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT01967823 ·Status: COMPLETED ·Phase: PHASE2